Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.03, with a volume of 622,547 shares traded.
Mateon Therapeutics Stock Performance
The firm has a 50-day moving average price of $0.02 and a two-hundred day moving average price of $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Use Stock Screeners to Find Stocks
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
